MedTrace Logo

Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents

NCT00207948 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2015-08-05

No results posted yet for this study

Summary

This was a feasibility study aimed at elevating protease inhibitors (PI) dosage as a part of active antiretroviral therapy (HAART). After the pharmacokinetics for the currently prescribed PI were determined,patients with a vIQ\<1 were eligible for a 50% dose increase for an 8 week time frame after which their vIQ would be reassessed to determine if increasing their PI dosage thereby increasing the bioavaiability would reduce their viral load.

Conditions

  • HIV Infections

Interventions

DRUG

Dose adjustment of Kaletra

Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations

Sponsors & Collaborators

  • Children's National Research Institute

    lead OTHER

Principal Investigators

  • Natella Y Rakhmanina, MD · Children's National Medical Center, Children's Research Institute

Eligibility

Min Age
4 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2009-05-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00207948 on ClinicalTrials.gov